First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma | Naviance

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

First-Ever Clinical Trial Demonstrates Safety, Molecular Readout and Promise of Pre- and Post-Surgery Immunotherapy Combination for Patients with Operable Mesothelioma

A novel treatment approach using combination immunotherapy before and after surgery shows promise for patients with operable mesothelioma, according to a new study led by investigators at the Johns Hopkins Kimmel Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy.

LEARN MORE

Recent Posts

Treatment Resistance in Prostate Cancer Elaine’s Story: A Journey of Strength, Faith, and Healing at Johns Hopkins In Extensive Sequencing Study, Scientists Find Few Links Between Cancer and Microbiome Johns Hopkins Investigators Create New Urine-based Test to ID Prostate Cancers New therapy kickstarts immune response to cancer Prostate Cancer Treatment: What to Do When It Stops Working 5 Healthy Habits That Help During Cancer Treatment Understanding Mammogram Results A 19-Year Fight Against Prostate Cancer Brings Man to Johns Hopkins Medicine